会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Arginine/ascorbic acid mixed powder as an oral supplement
    • 精氨酸/抗坏血酸混合粉末作为口服补充剂
    • US06552074B2
    • 2003-04-22
    • US09987179
    • 2001-11-13
    • Eiji KimotoFukumi Morishige
    • Eiji KimotoFukumi Morishige
    • A61K3134
    • A61K45/06A61K31/198A61K31/375A61K2300/00
    • A mixture obtained by mixing ascorbic acid powder with arginine powder in a weight ratio (ascorbic acid/arginine) of ⅕ to 20, especially ⅕ to ¼; and a supplement such as a nutrient preparation and a health-care food containing the mixture. Mixing of arginine powder and ascorbic acid powder in the weight ratios eliminates stringent taste specific to arginine and alleviates stringent feeling in the stomach (heartburn, nausea or vomiting) after oral intake thereof. The mixture prevents also peroxidative injuries of cells caused by an administration of a great amount of arginine alone. Further, mixing of arginine powder with ascorbic acid powder prevents browning of the mixture after long-term storage.
    • 将抗坏血酸粉末与精氨酸粉末(抗坏血酸/精氨酸)的重量比(1/5至20,特别是1/5至1/4)混合, 以及补充剂,例如营养制剂和含有该混合物的保健食品。 混合精氨酸粉末和抗坏血酸粉末的重量比消除了对精氨酸特异性的严格味道,并减轻了口服摄入后胃中的严重感觉(胃灼热,恶心或呕吐)。 该混合物还防止单独施用大量精氨酸引起的细胞的过氧化损伤。 此外,精氨酸粉末与抗坏血酸粉末的混合可以防止长期储存后混合物的褐变。
    • 6. 发明授权
    • Agents for regulation of colon cancer gene expression
    • 用于调节结肠癌基因表达的药剂
    • US06548539B1
    • 2003-04-15
    • US10090866
    • 2002-03-05
    • Stanislaw PikulDaniel R. SoppetPaul E. Young
    • Stanislaw PikulDaniel R. SoppetPaul E. Young
    • A61K3134
    • C07C323/42C07C323/40C07C323/41C07C323/44C07C2601/04C07C2601/08C07C2601/14C07D307/22
    • Compounds of the general structure according to Formula (I) wherein R1 is selected from alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl; R2 is selected from alkyl, alkenyl, alkyny, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl; R3 is selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; W is selected from Ch2, O and S; n is 0 to about 3: X is selected from S or O; Y, if present, is selected from a bond, aryl, NH, NR, O or S, where R3 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl; and Z, if present, can represent a bond or is selected from lower alkyl, O or S are disclosed. Also disclosed are uses of such compounds for treating a variety of disease conditions, including cancer.
    • 其中R 1选自烷基,烯基,炔基,杂烷基,卤代烷基,芳基,芳烷基,杂芳基,杂芳基烷基,环烷基和杂环烷基中的根据式(I)的通式结构的化合物; R 2选自烷基,烯基,炔基,杂烷基,卤代烷基,芳基烷基,杂芳基烷基,环烷基烷基和杂环烷基烷基; R 3选自芳基,杂芳基,环烷基和杂环烷基; W选自Ch2,O和S; n为0至约3:X选自S或O; Y如果存在,选自键,芳基,NH,NR,O或S,其中R 3选自氢,烷基,烯基,炔基,杂烷基,卤代烷基,芳基烷基,杂芳基烷基,环烷基烷基和杂环烷基烷基; 和Z如果存在,可以表示键或选自低级烷基,O或S。 还公开了这些化合物用于治疗各种疾病状况(包括癌症)的用途。